Compare AU

Compare XMET vs. DRUG

Compare shares and ETFs on the ASX that you can trade on Pearler.

BetaShares Energy Transition Metals ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Energy Transition Metals ETF (XMET) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

XMET

DRUG

Popularity

Low

Low

Pearlers invested

29

63

Median incremental investment

$1,007.50

$967.00

Median investment frequency

Monthly

Monthly

Median total investment

$1,086.36

$1,921.92

Average age group

> 35

26 - 35


Key Summary

XMET

DRUG

Strategy

XMET.AX was created on 2022-10-26 by BetaShares. The fund's investment portfolio concentrates primarily on materials equity. The investment objective of the Fund is to provide an investment return that aims to track the performance of the Nasdaq Sprott Energy Transition Materials Select Index, before taking into account fees and expenses

DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

Top 3 holdings

FIRST QUANTUM MINERALS LTD (6.03 %)

WHEATON PRECIOUS METALS CORP (5.85 %)

SOUTHERN COPPER CORP (5.64 %)

CHF - SWISS FRANC (0 %)

AUD - AUSTRALIA DOLLAR (0 %)

DKK - DANISH KRONE (0 %)

Top 3 industries

Other (65.48 %)

Materials (34.38 %)

Information Technology (0.14 %)

Other (75.53 %)

Communication Services (33.53 %)

Health Care (24.47 %)

Top 3 countries

Canada (36.79 %)

Australia (17.96 %)

United States (17.25 %)

United States (71.71 %)

Switzerland (8.14 %)

Denmark (6.30 %)

Management fee

0.69 %

0.57 %


Key Summary

XMET

DRUG

Issuer

BetaShares

BetaShares

Tracking index

Nasdaq Sprott Energy Transition Materials Select Index - AUD - Benchmark TR Net

Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD

Asset class

ETF

ETF

Management fee

0.69 %

0.57 %

Price

$8.23

$8.32

Size

$25.654 million

$182.401 million

10Y return

N/A

N/A

Annual distribution yield (5Y)

0.37 %

1.90 %

Market

ASX

ASX

First listed date

27/10/2022

08/08/2016

Purchase fee

$6.50

$6.50


Community Stats

XMET

DRUG

Popularity

Low

Low

Pearlers invested

29

63

Median incremental investment

$1,007.50

$967.00

Median investment frequency

Monthly

Monthly

Median total investment

$1,086.36

$1,921.92

Average age group

> 35

26 - 35


Pros and Cons

XMET

DRUG

Pros

  • Higher exposure to AU market

  • Higher exposure to US market

  • Lower management fee

  • Higher price growth

  • Higher distribution yield

Cons

  • Lower exposure to US market

  • Higher management fee

  • Lower price growth

  • Lower distribution yield

  • Lower exposure to AU market

XMET

DRUG

Higher exposure to AU market

Lower exposure to AU market

Lower exposure to US market

Higher exposure to US market

Higher management fee

Lower management fee

Lower price growth

Higher price growth

Lower distribution yield

Higher distribution yield

Home